MGNX News and Press, MacroGenics Inc. From 02/19/24

2024-02-19 22:23:22 ET Summary MacroGenics' stock has increased by 230% since September due to favorable macroeconomics and interest in antibody-drug conjugates. The company is testing vobramitamab duocarmazine for the treatment of metastatic castration-resistant prostate cancer. ...

2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...

2024-02-14 02:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 6.29% on the day to $18.41. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved ...

MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.67% on the day to $16.47. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved...

2024-02-03 10:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.93% on the day to $5.16. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved p...

2024-01-24 13:30:02 ET Guggenheim analyst issues UNDERPERFORM recommendation for MGNX on January 24, 2024 01:00PM ET. The previous analyst recommendation was Underperform. MGNX was trading at $11.89 at issue of the analyst recommendation. The overall analyst consensus : ...

2024-01-24 13:30:02 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for MGNX on January 24, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. MGNX was trading at $11.89 at issue of the analyst recommendation. The overall analys...

2024-01-23 13:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...